Panitumumab + Mfolfox6 Versus Bevacizumab + Mfolfox6 As First-Line Treatment of Wild-Type Ras Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis from the Brazilian Private Healthcare System Perspective.